Trust Company of Vermont’s Actinium Pharmaceuticals ATNM Stock Holding History

Trust Company of Vermont’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50	Closed	-$371	–	814
2023 Q2	$371	Hold	50	–	–	﹤0.01%	800
2023 Q1	$473	Hold	50	–	–	﹤0.01%	844
2022 Q4	$533	Hold	50	–	–	﹤0.01%	833
2022 Q3	$0	Hold	50	–	–	﹤0.01%	962
2022 Q2	$0	Buy	+50	New	+$284	﹤0.01%	890
2022 Q1	–	Sell	-50	Closed	–	–	338
2021 Q4	$0	Buy	+50	New	+$375	﹤0.01%	799
2021 Q3	–	Sell	-50	Closed	–	–	328
2021 Q2	$0	Hold	50	–	–	﹤0.01%	777
2021 Q1	$0	Hold	50	–	–	﹤0.01%	757
2020 Q4	$0	Hold	50	–	–	﹤0.01%	752
2020 Q3	$0	Hold	50	–	–	﹤0.01%	744
2020 Q2	$1K	Hold	50	–	–	﹤0.01%	739
2020 Q1	$0	Hold	50	–	–	﹤0.01%	872
2019 Q4	$0	Hold	50	–	–	﹤0.01%	915
2019 Q3	$0	Hold	50	–	–	﹤0.01%	988
2019 Q2	$0	Buy	+50	New	+$502	﹤0.01%	1017

Other funds holding ATNM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Trust Company of Vermont's ATNM Position: Q3 2023 in Review

Trust Company of Vermont sold out of Actinium Pharmaceuticals (ATNM) in Q3 2023, closing a stake of 50 shares — an estimated $371 sold.

Trust Company of Vermont first reported a position in ATNM in Q2 2019 and held it in 15 quarters. The position peaked at $1K in Q2 2020. 58 funds tracked by Wall St. Rank hold ATNM as of Q3 2023.

Trust Company of Vermont reported no remaining Actinium Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Trust Company of Vermont sold 50 Actinium Pharmaceuticals shares in Q3 2023, an estimated $371.
Trust Company of Vermont first reported a position in Actinium Pharmaceuticals in Q2 2019 and held it in 15 quarters.
Trust Company of Vermont's Actinium Pharmaceuticals position peaked at $1K in Q2 2020.
58 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2023.

Based on Trust Company of Vermont's 13F filing for Q3 2023, filed 27 Nov 2023.